Publications
293
Citations
2,797
Est. group size
~36
Recurring co-author estimate
Active years
23
Publishing since 2004
Ann-Kathrin Eisfeld studies the genetics of blood cancers, especially acute myeloid leukemia (AML) and related leukemias, focusing on how specific gene mutations (such as TP53, WT1, RAS, and IDH1) affect disease behavior, drug resistance, and patient outcomes. Her work combines genomic sequencing, clinical trial data, and emerging tools like deep learning to improve diagnosis, treatment selection, and understanding of disparities in care.
Publication output has grown substantially over the past decade, rising from single digits in 2017 to a sustained high volume (20-70+ per year) from 2022 onward.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Blood Cancer Journal · 2025
- Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials
Blood · 2025
- Abstract IA003: Integrated consideration of constitutional and somatic genetic features to improve knowledge and care of AML patients
Cancer Research · 2025
- Abstract 14: Molecular drivers of lineage bias in TP53-mutant therapy-related acute leukemias
Cancer Research · 2025
- Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay
Blood · 2025
- Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images
Blood · 2025
- RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Nature · 2024
- Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy
Haematologica · 2024
- Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US).
Journal of Clinical Oncology · 2024
- Genomic Analysis Defines Increased Circulating, Monocyte-Derived Macrophages That Promote Immune Suppression in Mouse Models of FGFR1-Driven Leukemogenesis and Defines a Multigene Signature That Predicts AML Outcomes
Blood · 2024
- Disparities in acute myeloid leukemia treatments and outcomes
Current Opinion in Hematology · 2023
- Clinical and Prognostic Implications of <i>WT1</i> Mutations in De Novo and Relapsed Acute Myeloid Leukemia
Blood · 2023
- The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Journal of Clinical Oncology · 2023
- Table S1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions
2023
- Table S1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions
2023
- Blood×79
- Leukemia×12
- Cancer Research×9
- Blood Advances×6
- Blood Cancer Discovery×6
- Deedra Nicolet
Medicine · The Ohio State University
- Uma Borate
Medicine · The Ohio State University
- Priyanka Mehta
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Krzysztof Mrózek
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile